Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › TX › Houston › NPI 1326104613
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $8.76M by Medicaid between Jan 2018 and Dec 2024, across 271 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 8.5% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
HOUSTON, TX 77072
33aNPI1326104613assigned 12/29/2006
33bProvider typeClinical Medical Laboratory
28Total paid$8.76M
24GClaims2,693,864
24DCodes billed271
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#22 of 436
Median peer was paid$17K
This provider vs. median508×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018505,749$1.61M
2019485,450$1.73M
2020424,639$1.57M
2021448,216$1.83M
2022352,105$807K
2023270,887$709K
2024incomplete206,818$504K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 8.5% 45,549 38,549 $741K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 8.3% 45,083 38,148 $731K
80050 General health panel 7.5% 42,168 36,570 $660K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 5.6% 10,320 9,238 $487K
80061 Lipid panel 5.0% 186,420 175,422 $438K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 4.2% 40,337 34,531 $372K
80053 Comprehensive metabolic panel 3.6% 230,141 213,844 $316K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3.6% 14,298 9,455 $314K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.5% 67,258 61,106 $308K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 3.4% 19,363 16,383 $298K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.5% 201,458 184,606 $219K
84443 Thyroid stimulating hormone (TSH) 2.3% 120,172 114,598 $203K
259 more codes
83036 Hemoglobin; glycosylated (A1C) 2.3% 149,472 $201K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.8% 14,102 $156K
87086 Culture, bacterial; quantitative colony count, urine 1.6% 71,854 $138K
86480 1.4% 7,159 $125K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.4% 6,558 $124K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.3% 8,833 $118K
86803 1.3% 24,540 $116K
80074 1.3% 10,324 $112K
86003 1.3% 2,725 $110K
87088 1.2% 57,925 $103K
80081 1.1% 2,569 $98K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.0% 7,027 $92K
82607 <1% 27,333 $69K
84439 <1% 42,926 $65K
87522 Neg quan hep c or qual rna <1% 4,122 $63K
82728 <1% 24,930 $60K
84153 <1% 18,029 $58K
87070 <1% 14,272 $50K
86769 <1% 2,470 $47K
86592 <1% 28,478 $46K
87186 <1% 30,012 $45K
87340 <1% 13,280 $43K
87077 <1% 29,039 $43K
85027 <1% 34,893 $42K
82746 <1% 16,494 $41K
83970 <1% 14,426 $41K
86696 <1% 3,989 $40K
83013 <1% 2,719 $37K
83655 <1% 13,556 $35K
84481 <1% 16,011 $35K
83550 <1% 23,295 $34K
87799 <1% 2,814 $32K
84702 <1% 4,797 $32K
80048 Basic metabolic panel (calcium, ionized) <1% 29,874 $31K
82570 <1% 51,620 $30K
81513 <1% 1,637 $29K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 2,215 $29K
84403 <1% 5,609 $29K
87081 <1% 8,311 $28K
83540 <1% 27,049 $27K
86695 <1% 3,875 $26K
82043 <1% 38,767 $25K
83880 <1% 7,344 $24K
83001 <1% 3,542 $23K
86038 <1% 6,724 $22K
81001 <1% 51,528 $22K
86706 <1% 6,498 $21K
82105 <1% 3,679 $21K
84436 <1% 18,314 $20K
36415 Collection of venous blood by venipuncture <1% 235,959 $20K
86780 <1% 2,741 $20K
82652 <1% 5,077 $20K
84146 <1% 3,261 $20K
82670 <1% 2,450 $19K
86704 <1% 5,628 $19K
86708 <1% 5,107 $19K
83735 <1% 25,035 $18K
82784 <1% 4,645 $18K
80348 <1% 2,038 $16K
83002 <1% 2,312 $15K
87147 <1% 8,807 $15K
80354 <1% 2,051 $15K
82950 <1% 6,471 $15K
86140 <1% 19,146 $15K
84480 <1% 8,589 $15K
82785 <1% 1,746 $13K
82274 <1% 2,909 $13K
80055 <1% 1,976 $13K
85652 <1% 24,475 $12K
86762 <1% 1,531 $12K
87536 <1% 391 $12K
84479 <1% 10,619 $12K
80076 <1% 6,658 $12K
83021 <1% 1,161 $12K
84550 <1% 21,472 $12K
87480 <1% 1,133 $11K
87510 <1% 1,133 $11K
80361 <1% 1,350 $10K
85660 <1% 3,880 $10K
86376 <1% 2,222 $9K
85610 <1% 17,386 $9K
87660 <1% 1,133 $9K
82248 <1% 11,148 $9K
80164 <1% 4,860 $9K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 281 $9K
80346 <1% 1,005 $9K
87512 <1% 621 $8K
82550 <1% 8,655 $8K
80349 <1% 1,088 $8K
81003 <1% 23,660 $8K
82951 <1% 1,256 $8K
86235 <1% 1,103 $8K
84144 <1% 939 $8K
86431 <1% 6,428 $7K
88142 <1% 778 $7K
84156 <1% 16,640 $7K
80362 <1% 853 $7K
83525 <1% 2,071 $7K
87075 <1% 2,863 $6K
83690 <1% 4,722 $6K
84703 <1% 1,741 $6K
80365 <1% 728 $6K
86317 <1% 1,447 $6K
88141 <1% 649 $6K
86160 <1% 2,099 $6K
84100 <1% 17,075 $6K
86850 <1% 1,243 $5K
84402 <1% 1,137 $5K
80069 <1% 6,979 $5K
85730 <1% 5,630 $5K
87209 <1% 642 $5K
83520 <1% 2,031 $5K
83516 <1% 1,349 $5K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 133 $4K
83615 <1% 4,489 $4K
82150 <1% 3,475 $4K
82378 <1% 2,106 $4K
87205 <1% 3,699 $3K
84460 <1% 3,194 $3K
87427 <1% 571 $3K
86039 <1% 1,139 $3K
85018 <1% 3,446 $3K
82677 <1% 242 $3K
87045 <1% 665 $3K
85045 <1% 2,980 $3K
80324 <1% 326 $2K
87177 <1% 642 $2K
86360 <1% 123 $2K
84450 <1% 2,738 $2K
82565 <1% 3,742 $2K
86200 <1% 1,230 $2K
87046 <1% 538 $2K
86901 <1% 1,345 $2K
86900 <1% 1,341 $2K
82533 <1% 764 $2K
82977 <1% 2,029 $2K
86787 <1% 362 $2K
83020 <1% 314 $2K
84132 <1% 1,633 $2K
87338 <1% 335 $2K
82947 <1% 2,363 $2K
87497 <1% 800 $2K
82952 <1% 978 $2K
86300 <1% 422 $2K
86336 <1% 242 $2K
85014 <1% 2,540 $2K
99199 Unlisted special service, procedure or report <1% 129 $2K
83698 <1% 658 $2K
86765 <1% 204 $1K
80178 <1% 1,712 $1K
84165 <1% 1,454 $1K
86593 <1% 799 $1K
82310 <1% 2,354 $1K
80197 <1% 2,221 $1K
86735 <1% 187 $1K
84681 <1% 457 $1K
86800 <1% 495 $1K
80177 <1% 1,801 $1K
82627 <1% 191 $1K
86225 <1% 831 $1K
82330 <1% 1,205 $1K
87449 <1% 316 $1K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 204 $1K
86008 <1% 27 $991.59
80359 <1% 213 $959.76
81015 <1% 1,454 $957.46
81025 <1% 232 $952.02
86141 <1% 996 $928.72
82247 <1% 1,571 $901.59
86255 <1% 986 $887.40
80335 <1% 171 $851.40
84520 <1% 2,552 $834.51
87902 <1% 24 $806.60
80320 <1% 86 $794.64
83090 <1% 308 $793.65
84154 <1% 492 $768.20
80185 <1% 710 $746.60
80373 <1% 114 $745.62
84134 <1% 459 $716.34
80051 <1% 691 $703.05
80156 <1% 529 $697.71
80321 <1% 121 $689.56
80358 <1% 103 $648.66
87254 <1% 85 $637.10
86334 <1% 628 $634.50
80369 <1% 99 $618.28
84425 <1% 372 $600.94
80353 <1% 66 $590.55
85379 <1% 238 $547.67
80372 <1% 89 $540.94
83014 <1% 366 $505.92
84155 <1% 1,824 $480.42
84484 <1% 98 $460.16
85041 <1% 271 $453.78
82040 <1% 1,735 $451.28
82140 <1% 796 $448.16
80368 <1% 61 $443.76
87324 <1% 108 $431.59
84478 <1% 179 $370.22
82610 <1% 337 $349.16
83992 <1% 35 $339.78
84075 <1% 1,281 $325.57
83704 <1% 712 $319.06
80367 <1% 49 $263.16
86146 <1% 21 $257.32
80356 <1% 21 $248.54
82172 <1% 1,098 $233.07
99001 <1% 66 $232.32
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 17 $225.60
84270 <1% 70 $213.37
83721 <1% 309 $194.34
86812 <1% 12 $168.24
87329 <1% 25 $159.12
83883 <1% 460 $158.00
83695 <1% 811 $140.25
80345 <1% 18 $114.43
87101 <1% 32 $108.77
80366 <1% 22 $99.33
80360 <1% 24 $99.33
86304 <1% 39 $75.15
86301 <1% 58 $75.15
80355 <1% 22 $70.98
86021 <1% 62 $54.35
80175 <1% 72 $47.85
82465 <1% 56 $44.10
84466 <1% 15 $39.93
84295 <1% 219 $39.78
83519 <1% 21 $33.84
85007 <1% 53 $32.24
81511 <1% 100 $30.70
82525 <1% 12 $26.88
80158 <1% 240 $26.08
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 1,069 $25.89
86364 <1% 174 $18.44
82435 <1% 55 $18.07
83789 <1% 13 $16.99
84432 <1% 14 $11.60
85048 <1% 13 $11.22
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 5,930 $3.39
83718 0% 31 $0.00
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 0% 32 $0.00
84166 0% 41 $0.00
83876 0% 17 $0.00
86015 0% 13 $0.00
80235 0% 12 $0.00
86036 0% 12 $0.00
86709 0% 12 $0.00
81596 0% 54 $0.00
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count 0% 420 $0.00
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous 0% 1,331 $0.00
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) 0% 555 $0.00
83010 0% 75 $0.00
80201 0% 13 $0.00
80184 0% 53 $0.00
87517 0% 101 $0.00
82390 0% 12 $0.00
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision 0% 40 $0.00
80183 0% 12 $0.00
86381 0% 14 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (SR. VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.